Skip to main content
. 2019 Aug 3;11(8):391. doi: 10.3390/pharmaceutics11080391

Figure 4.

Figure 4

Uptake of Rhodamine-labelled non-targeted (A,D) or VCAM-1 targeted (B,C,E,F) nanoparticles by EA.hy926 cells. Confluent endothelial cells EA.hy926 activated or not with Tumor Necrosis Factor (TNF)-α (20 ng/mL) for 18 h were incubated for the indicated times with two different doses of nanoparticles. Fluorescence micrographs are shown in (A–C) (scale bar: 50 µm). In (D–F) a quantitative assessment of the uptake by flow cytometry corresponding to the upper panels (A–C, respectively). It can be observed that nanoparticles were taken up in a dose- and time-dependent manner and that TNF-α influenced only the uptake of VCAM-1 targeted particles. Coupling ratio of peptide (µg) and total lipid (µmol) was 1:1 (B,E) and 10:1 (C,F).